Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 50 publications.

Rothman KJ. The public-health mindset : review of "The public health approach - population thinking from the black death to COVID-19" by Alfredo Morabia, Johns Hopkins University Press, 2023. Eur J Epidemiol. 2024 Mar;39(3):323-4. doi: 10.1007/s10654-024-01108-6

Moss E, Burrell A, Lee J, Reichenbach D, Mitchell S, Yan S, Thiruvillakkat K. Economic and humanistic burden in kidney transplant rejection: a literature review. Expert Rev Pharmacoecon Outcomes Res. 2024 Mar;24(3):343-52. doi: 10.1080/14737167.2024.2305140

Fernandez MM, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Disease and economic burden of surgery in desmoid tumors: a review. Expert Rev Pharmacoecon Outcomes Res. 2023 Jul;23(6):607-18. doi: 10.1080/14737167.2023.2203915

Poulos C, Xu Y, Botha W, Leach C, Wrobleski KK, Gordon K, Missmer SA, Estes SJ. A discrete-choice experiment study of physicians' prioritization of attributes of medical treatments for endometriosis-associated pain. Expert Rev Pharmacoecon Outcomes Res. 2023 Jan;23(1):111-21. doi: 10.1080/14737167.2023.2152006

Smith LH, Garcia-Albeniz X, Chan JM, Zhao S, Cowan JE, Broering JM, Cooperberg MR, Carroll PR, Hernan MA. Emulation of a target trial with sustained treatment strategies: an application to prostate cancer using both inverse probability weighting and the g-formula. Eur J Epidemiol. 2022 Dec 1;37(12):1205-13. doi: 10.1007/s10654-022-00929-7

Khan A, Lin P, Kamdar N, Peterson M, Mahmoudi E. Potentially preventable hospitalizations and use of preventive services among people with multiple sclerosis: large cohort study, USA. Mult Scler Relat Disord. 2022 Dec;68:104105. doi: 10.1016/j.msard.2022.104105

Garcia-Albeniz X, Del Amo J, Polo R, Morales-Asencio JM, Hernan MA. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. Eur J Epidemiol. 2022 Aug 9;37(8):789-96. doi: 10.1007/s10654-022-00891-4

Herring W, Ciarametaro M, Mauskopf J, Wamble D, Sils B, Dubois R. What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States. Expert Rev Pharmacoecon Outcomes Res. 2022 Jun;22(4):529-41. doi: 10.1080/14737167.2022.2035219

Kamudoni P, Amtmann D, Johns J, Cook KF, Salem R, Salek S, Raab J, Middleton R, Repovic P, Alschuler KN, von Geldern G, Wundes A, Barrett A, Olayinka-Amao B, Henke C. The validity, responsiveness, and score interpretation of the PROMISnq Physical Function - Multiple Sclerosis 15a short form in multiple sclerosis. Mult Scler Relat Disord. 2022 Jun;62:103753. doi: 10.1016/j.msard.2022.103753

Flem E, Graham J, Yi Z, Wisloff T, Johnson KD. Cost and health impact analysis of herpes zoster vaccination in Norway. Expert Rev Pharmacoecon Outcomes Res. 2022 Mar;22(2):315-26. doi: 10.1080/14737167.2021.1973893

Alemany S, Avella-Garcia C, Liew Z, Garcia Esteban R, Inoue K, Cadman T, Lopez-Vicente M, Gonzalez L, Riano Galan I, Andiarena A, Casas M, Margetaki K, Strandberg-Larsen K, Lawlor DA, EL Marroun H, Tiemeier H, Iniguez C, Tardon A, Santa-Marina L, Julvez J, Porta D, Chatzi L, Sunyer J. Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms in childhood: meta-analysis in six European population-based cohorts. Eur J Epidemiol. 2021 Oct;36(10):993-1004. doi: 10.1007/s10654-021-00754-4

Rothman KJ. The origin of Modern Epidemiology, the book. Eur J Epidemiol. 2021 Aug;36(8):763-5. doi: 10.1007/s10654-021-00790-0

Poudel N, Banjara B, Kamau S, Frost N, Ngorsuraches S. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2021 Feb;48:102720. doi: 10.1016/j.msard.2020.102720

Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871

Poulos C, Soliman AM, Tekin S, Agarwal SK. Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States. Expert Rev Pharmacoecon Outcomes Res. 2020 Nov 3;1-9. doi: 10.1080/14737167.2021.1832468

Penner I-K, McDougall F, Brown TM, Slota C, Doward L, Julian L, Belachew S, Miller D. Exploring the impact of fatigue in progressive multiple sclerosis: a mixed-methods analysis. Mult Scler Relat Disord. 2020 Aug;43:102207. doi: 10.1016/j.msard.2020.102207

Himmler S, Mueller M, Sherif B, Ostwald D. A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany. Expert Rev Pharmacoecon Outcomes Res. 2019 Jul 29. doi: 10.1080/14737167.2019.1644169

Gignac F, Romaguera D, Fernandez-Barres S, Phillipat C, Garcia-Esteban R, Lopez-Vicente M, Vioque J, Fernandez-Somoano A, Tardon A, Iniguez C, Lopez-Espinosa MJ, Garcia de la Hera M, Amiano P, Ibarluzea J, Guxens M, Sunyer J, Julvez J. Maternal nut intake in pregnancy and child neuropsychological development up to 8 years old: a population-based cohort study in Spain. Eur J Epidemiol. 2019 May;34(7):661-73. doi: 10.1007/s10654-019-00521-6

Vinceti M, Filippini T, Rothman KJ. Selenium exposure and the risk of type 2 diabetes: a systematic review and meta-analysis. Eur J Epidemiol. 2018 Sep;33(0):789-810. doi: 10.1007/s10654-018-0422-8.

Andronis L, Oppong RA, Manga N, Senanayake E, Gopal S, Charman S, Giri R, Luckraz H. Is the Venner-PneuX endotracheal tube system a cost-effective option for post cardiac surgery care? Ann Thorac Surg. 2018 Sep;106(3):757-63. doi: 10.1016/j.athoracsur.2018.03.058

Rothman KJ. The growing rift between epidemiologists and their data. Eur J Epidemiol. 2017 Oct;32(10):863-5. doi: 10.1007/s10654-017-0314-3

Garcia-Albeniz X, Hsu J, Hernan MA. The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening. Eur J Epidemiol. 2017 Jun;32(6):495-500. doi: 10.1007/s10654-017-0287-2

Heritier H, Vienneau D, Foraster M, Eze IC, Schaffner E, Thiesse L, Rudzik F, Habermacher M, Kopfli M, Pieren R, Brink M, Cajochen C, Wunderli JM, Probst-Hensch N, Roosli M. Transportation noise exposure and cardiovascular mortality: a nationwide cohort study from Switzerland. Eur J Epidemiol. 2017 Apr;32(4):307-15. doi: 10.1007/s10654-017-0234-2

Basu A, Dalal A, Canonica GW, Forshag M, Yancey SW, Nagar S, Bell CF. Economic analysis of the Phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):121-31. doi: 10.1080/14737167.2017.1298444

Clark M, DiBenedetti D, Perez V. Cognitive dysfunction and work productivity in major depressive disorder. Expert Rev Pharmacoecon Outcomes Res. 2016 Jun 8. doi: 10.1080/14737167.2016.1195688

Rothman KJ. Disengaging from statistical significance - Commentary. Eur J Epidemiol. 2016 May;31(5):443-4. doi: 10.1007/s10654-016-0158-2

Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, Altman DG. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016 Apr;31(4):337-50. doi: 10.1007/s10654-016-0149-3

Garcia-Albeniz X, Hsu J, Lipsitch M, Logan RW, Hernandez-Díaz S, Hernan MA. Infective endocarditis and cancer in the elderly. Eur J Epidemiol. 2016 Jan;31(1):41-9. doi: 10.1007/s10654-015-0111-9

Hatch EE, Hahn KA, Mikkelsen EM, Riis EH, Sorensen HT, Rothman KJ, Wise LA. Pre-gravid oral contraceptive use in relation to birth weight: a prospective cohort study. Eur J Epidemiol. 2015 Nov;30(11):1199-208.

Brennan VK, Mauskopf JA, Colosia AD, Copley-Merriman K, Hass B, Palencia R. Utility estimates for patients with type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):111-23.

Chen WH, McLeod L, Nelson LM, Williams VS, Fehnel SE. Quantitative challenges facing patient-centered outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2014 Jun 14;14(3):379-86.

Vinceti M, Malagoli C, Rothman KJ, Rodolfi R, Astolfi G, Calzolari E, Puccini A, Bertolotti M, Lunt M, Paterlini L, Martini M, Nicolini F. Risk of birth defects associated with maternal pregestational diabetes. Eur J Epidemiol. 2014 Jun;29(6):411-8.

Von Schéele B, Mauskopf J, Brodtkorb TH, Ainsworth C, Berardo CG, Patel A. Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):235-57. doi: 10.1586/14737167.2014.891443

Fehnel S, DeMuro C, McLeod L, Coon C, Gnanasakthy A. FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):441-6.

Karve SJ, Panish JM, Dirani RG, Candrilli SD. Health care utilization and costs among Medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses. Health Outcomes Res Med. 2012 Nov 1;3(4):e183-94.

Vinceti M, Rothman KJ, Crespi CM, Sterni A, Cherubini A, Guerra L, Maffeis G, Ferretti E, Fabbi S, Teggi S, Consonni D, De Girolamo G, Meggiato A, Palazzi G, Paolucci P, Malagoli C. Leukemia risk in children exposed to benzene and PM10 from vehicular traffic: a case–control study in an Italian population. Eur J Epidemiol. 2012 Oct 1;27(10):781-90.

Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun 1;12(3):357-71.

DeMuro CJ, Lewis SA, DiBenedetti DB, Price MA, Fehnel SE. Successful implementation of cognitive interviews in special populations. Expert Rev Pharmacoecon Outcomes Res. 2012 Apr 1;12(2):181-7.

Karve S, Misurski D, Miller J, Davis KL. Costs of sequelae associated with invasive meningococcal disease: findings from a US managed care population. Health Outcomes Res Med. 2011 Nov 1;2(4):e215-26.

Rothman KJ, Stein Z, Susser M. Rebuilding bridges: what is the real role of social class in disease occurrence? Eur J Epidemiol. 2011 Jun;26(6):431-2.

McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: uS FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011 Apr 1;11(2):163-9.

Wolowacz SE. Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery. Expert Rev Pharmacoecon Outcomes Res. 2011 Feb 1;11(1):9-25.

Huybrechts KF, Mikkelsen EM, Christensen T, Riis AH, Hatch EE, Wise LA, Sorensen HT, Rothman KJ. A successful implementation of e-epidemiology: the Danish pregnancy planning study 'Snart-Gravid'. Eur J Epidemiol. 2010 May 1;25(5):297-304.

Rothman KJ. Curbing type I and type II errors. Eur J Epidemiol. 2010 Apr 1;25(4):223-4.

Lundbye-Christensen S, Dethlefsen C, Gorst-Rasmussen A, Fischer T, Schønheyder HC, Rothman KJ, Sørensen HT. Examining secular trends and seasonality in count data using dynamic generalized linear modeling: a new methodological approach illustrated with hospital discharge data on myocardial infarction. Eur J Epidemiol. 2009;24(5):225-30.

Mauskopf JA, Earnshaw SR, Mullins C. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res. 2005 Feb;5(1):65-79.

Skriver MV, Pedersen L, Stang P, Lund L, Rothman KJ, Sorensen HT. The month of birth does not affect the risk of hypospadias. Eur J Epidemiol. 2004 Dec 1;19(12):1135-6.

Rothman KJ, Mahon BE. Confounding and effect-measure modification in the evaluation of immunogenic agents. Eur J Epidemiol. 2004 Mar;19(3):205-7.

Ryan M, Watson V, Amaya-Amaya M. Methodological issues in the monetary valuation of benefits in healthcare. Expert Rev Pharmacoecon Outcomes Res. 2003 Dec;3(6):717-27. doi: 10.1586/14737167.3.6.717

Duff SB, Mordin MM. Strategies for assessing health economic and quality-of-life outcomes in multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2002 Dec;2(6):577-87.